Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Public ClinicalTrials.gov record NCT04221893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.
Study identification
- NCT ID
- NCT04221893
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 28 participants
Conditions and interventions
Conditions
- Stage IV Esophageal Adenocarcinoma
- Stage IV Esophageal Squamous Cell Carcinoma
- Stage IV Gastric Cancer
- Stage IV Adenocarcinoma of the Gastroesophageal Junction
- Stage IVA Esophageal Adenocarcinoma
- Stage IVA Esophageal Squamous Cell Carcinoma
- Stage IVA Gastric Cancer
- Stage IVA Adenocarcinoma of the Gastroesophageal Junction
- Stage IVB Esophageal Adenocarcinoma
- Stage IVB Esophageal Squamous Cell Carcinoma
- Stage IVB Gastric Cancer
- Stage IVB Gastroesophageal Junction Adenocarcinoma
- Metastatic Anal Canal Carcinoma
- Metastatic Colorectal Carcinoma
- Metastatic Esophageal Carcinoma
- Metastatic Gastric Carcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Hepatocellular Carcinoma
- Metastatic Malignant Digestive System Neoplasm
- Metastatic Small Intestinal Carcinoma
- Pancreatobiliary Carcinoma
- Pathologic Stage IV Gastric Cancer AJCC v8
- Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
- Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
- Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
- Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
- Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8
- Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Stage IV Anal Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Stage IVC Colorectal Cancer AJCC v8
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 6, 2020
- Primary completion
- Apr 29, 2027
- Completion
- Apr 29, 2028
- Last update posted
- Aug 13, 2026
2020 – 2028
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94143 | Recruiting |
| John Muir Medical Center-Walnut Creek | Walnut Creek | California | 94598 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04221893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04221893 live on ClinicalTrials.gov.